IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells  by Yoshiki, Ryutaro et al.
IL-23 from Langerhans Cells Is Required for
the Development of Imiquimod-Induced
Psoriasis-Like Dermatitis by Induction of
IL-17A-Producing cd T Cells
Ryutaro Yoshiki1, Kenji Kabashima2, Tetsuya Honda2, Satoshi Nakamizo2, Yu Sawada2, Kazunari Sugita1,
Haruna Yoshioka1, Shun Ohmori1, Bernard Malissen3, Yoshiki Tokura4 and Motonobu Nakamura1
Psoriasis is a common chronic inflammatory skin disease that involves dysregulated interplay between immune
cells and keratinocytes. Recently, it has been reported that IL-23 induces CCR6þ gd T cells, which have the pivotal
role in psoriasis-like skin inflammation in mice of producing IL-17A and IL-22. Langerhans cells (LCs) are a subset
of dendritic cells that reside in the epidermis and regulate immune responses. The role of LCs has been
extensively investigated in contact hypersensitivity, but their role in psoriasis remains to be clarified. In this study,
we focused on Th17-related factors and assessed the role of LCs and gd T cells in the development of psoriasis
using a mouse psoriasis model triggered by topical application of imiquimod (IMQ). LC depletion by means of
diphtheria toxin (DT) in Langerin DT receptor–knocked-in mice suppressed hyperkeratosis, parakeratosis, and ear
swelling in the IMQ-treated regions. In addition, LC-depleted mice showed decreased levels of Th17-related
cytokines in IMQ-treated skin lesions. Moreover, the IMQ-treated skin of LC-depleted mice showed a decreased
number of IL-17A-producing CCR6þ gd T cells. These results suggest that LCs are required for the development of
psoriasis-like lesions induced by IMQ in mice.
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INTRODUCTION
Psoriasis is an inflammatory epidermal hyperproliferative skin
disease that affects 2–3% of the population in Caucasians. In
this disease, patients develop erythematous papules and scaly
plaques over the skin surface. Several lines of evidence, such
as the presence of activated CD4þ and CD8þ T cells in
psoriatic plaques (Ferenczi et al., 2000), the results of studies
on human skin xenografts in mice (Boyman et al., 2004), and
the therapeutic efficacy of T cell– targeted drugs (Di Cesare
et al., 2009), have suggested the involvement of T cell–
mediated immune responses in this disease. In addition, the
expression levels of IL-1, tumor necrosis factor (TNF), IL-12,
IL-17, IL-22, and IL-23 are elevated in psoriatic skin in humans
(Di Cesare et al., 2009), and IL-23R gene polymorphisms are
associated with psoriasis (Capon et al., 2007). These findings
suggest the involvement of these cytokines in the pathogenesis
of this skin disease.
Recent studies have demonstrated that the IL-23/Th17
pathway is linked to a number of inflammatory diseases,
including psoriasis and animal models of multiple sclerosis,
arthritis, and inflammatory bowel disease (Cua et al., 2003).
The most persuasive evidence for the role of IL-23/Th17 in
psoriasis comes from clinical studies. Treatment with an anti-
IL-12/IL-23p40 Ab (ustekinumab) is effective against psoriasis
(Krueger et al., 2007). TNF-a-neutralizing antibodies are also
widely used to treat psoriasis and significantly improve
psoriasis area severity index scores. Notably, inhibition of
TNF-a by a soluble TNF-a receptor–neutralizing antibody
(etanercept) was associated with reduced Th17 responses
(Zaba et al., 2007). As Th1 responses were not affected by
the administration of etanercept, this finding suggests that
Th17 cells are particularly important in driving psoriasis.
Consistently, amelioration of psoriasis has been associated
with reduced Th17 responses (Zaba et al., 2007). Th17
cytokines, principally IL-17A and IL-22, exert profound
effects on keratinocytes (Nograles et al., 2008). In psoriasis
lesions, keratinocytes are activated and proliferate at
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substantially faster rates than normal keratinocytes (Iizuka,
1994). IL-17A has been shown to induce cytokine and
chemokine production by keratinocytes, whereas IL-22
induces antimicrobial peptide production by keratinocytes
and is a direct potent stimulator of keratinocyte growth
(Nograles et al., 2008).
More recently, topical treatment with imiquimod (IMQ), a
ligand for Toll-like receptor (TLR) 7 and TLR8, was reported as
a novel mouse model for psoriasis-like skin inflammation
inducing acanthosis, parakeratosis, and a mixed inflammatory
infiltrate (van der Fits et al., 2009). IMQ is used in humans for
topical treatment of genital and perianal warts caused by
human papillomavirus, actinic keratosis, and superficial basal
cell carcinoma. Clinical application of IMQ can induce
psoriasis or exacerbate the disease in patients with well-
controlled psoriasis (Fanti et al., 2006). In mice, IMQ-
induced dermatitis development is critically dependent on
the IL-23/IL-17 axis (van der Fits et al., 2009). Moreover,
administration of IL-23 into mouse skin results in the
epidermal recruitment of CCR6þ cells, a subtype of gd T
cells that produces IL-17A (Mabuchi et al., 2011), and IMQ-
treated mice show increased numbers of IL-17-producing gd
T cells (Roller et al., 2012). However, it remains unclear
how these IL-17-producing gd T cells are induced in the
IMQ-treated skin, specifically in regard to the involvement of
skin resident–dendritic cells (DCs).
Recent immunological studies have demonstrated that
there are Langerhans cells (LCs), Langerin dermal DCs
(dDCs), and Langerinþ dDCs in murine skin (Ginhoux
et al., 2007). LCs are a subset of skin-resident DCs that
form a dense network in the epidermis (Romani et al., 2010;
Egawa and Kabashima, 2011). The role of LCs has been well
studied in contact hypersensitivity, the induction of which is a
classical technique permitting the examination of cutaneous
adaptive immune responses (Honda et al., 2012; Kaplan
et al., 2012). Transgenic mice with an inducible or
constitutive ablation of LCs showed enhanced contact
hypersensitivity (Kaplan et al., 2005), whereas other LC
ablation mouse models developed reduced or unaffected
contact hypersensitivity (Bennett et al., 2007).
In this study, we explored the role of LCs in a mouse model
in which psoriasis-like skin inflammation is triggered by topical
application of IMQ. LC–depleted mice showed reduced ear
swelling and decreased levels of Th17-related cytokines in
IMQ-treated skin regions. LC-depleted IMQ-treated skin
showed decreased IL-17A production and expression of CCR6
from skin gd T cells. We also found that LCs produce IL-23 in
IMQ-applied skin regions and that IL-23-producing cells were
reduced at draining lymph nodes after IMQ application. These
results suggest that LCs are required for generation of psoriasis-
like lesions in response to IMQ in mouse models.
RESULTS
LC–depleted mice show reduced IMQ-induced psoriasis-like skin
inflammation
Consistent with a previous report (van der Fits et al., 2009),
topical application of IMQ on the skin of wild-type mice for
5 days induced psoriasis-like lesions featuring redness, scales,
and crust formation. To evaluate the function of LCs in the
pathogenesis of psoriasis, LCs were depleted with diphtheria
toxin (DT) in Langerin-DT receptor (DTR)–knocked-in mice.
LCs were completely ablated from the epidermis within 24 h
after injection of DT. We also investigated whether Langerinþ
dDCs are involved in IMQ-induced psoriasis-like skin
inflammation. It has been reported that Langerinþ dDCs
recolonize in the dermis in 5 days or less after DT injection
(Bursch et al., 2007). Ten days after DT injection, LCs are still
absent in the epidermis but dDCs are present (Supplementary
Figure 1a online). IMQ cream was applied on both ears of LC/
Langerinþ dDC–depleted mice or on ears of LC-depleted
mice for 5 consecutive days. When the absolute number of
each LC/DC subset per skin specimen was calculated, the
subset of Langerinþ dDCs absolutely disappeared by IMQ
application, but that of LCs and Langerin dDCs was not
affected (Supplementary Figure 1a, b, d, e, f online). In
addition, the IMQ application increased the number of
Gr1þ cells regardless of the depletion of LCs or Langerinþ
dDCs (Supplementary Figure 1c, g online). Ear thickness was
measured on day 6 after the start of IMQ application.
Compared with IMQ-treated non-DT control mice, LC-
depleted and IMQ-treated mice showed milder increases in
ear thickness (Figure 1a and b). To exclude the involvement of
newly differentiated LCs, we applied a daily DT treatment and
IMQ application for 5 consecutive days to ensure efficient
ablation of LC throughout the course of disease. A daily DT
treatment and IMQ application did not affect the result of the
ear thickness change (Supplementary Figure 2 online). Micro-
scopic evaluation of skin sections from mice treated with IMQ
revealed changes characteristic of psoriasis-like lesions, such
as acanthosis, parakeratosis, desquamation, and dermal
infiltration of immune cells. In contrast, IMQ administration
had qualitatively and quantitatively fewer effects on
Langerinþ cell (including LCs and Langerinþ dDCs)–depleted
mice (IMQ application 1 day after DT treatment; Day 1) or
LC-depleted mice (IMQ application 10 days after DT treat-
ment; Day 10) (Figure 1a). Hyperproliferation of keratinocytes
in IMQ-induced psoriatic regions was also monitored by
immunohistochemical staining of Stat3 and Ki67. IMQ-treated
skin keratinocytes of control C57BL/6 mice were highly
positive for Stat3 and Ki67 as compared with IMQ-treated
Langerinþ cell–depleted (Day 1) or LC-depleted mice
(Day 10) (Figure 1a and c). These findings indicate that LCs
are critical for the induction of IMQ-induced psoriasis-skin
inflammation.
LC–depleted skin shows decreased IL-12/23p19, IL-12/23p40,
IL-17A, IL-22, and TNF-a mRNA induction by IMQ
Recently, the roles of Th1 and Th17 cytokines in the
pathogenesis of IMQ-induced psoriasis-like skin inflammation
have been demonstrated (van der Fits et al., 2009). To
characterize immune responses in IMQ-treated skin of LC-
depleted mice, the expression of cytokines was measured by
real-time PCR. IMQ cream was applied on both ears of LC/
Langerinþ dDC–depleted mice or only LC-depleted mice for 5
consecutive days. On day 6, the mice were killed and mRNA
from both ears was extracted. In control C57BL/6J mice,
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application of IMQ induced IL-12/23p19, IL-12/23p40,
IL-17A, IL-22, and TNF-a mRNA expression (Figure 2a–e),
whereas expression of IL-12p35 mRNA was not detected
by real-time PCR (data not shown). In LC-depleted and
IMQ-treated mice, the induction of IL-12/23p19, IL-12/
23p40, IL-17A, IL-22, and TNF-a mRNAs was suppressed
on both day 1 and day 10 (Figure 2a–e). As IL-23 maintains
IL-17-producing cells, the above findings suggest that
IMQ stimulates the production of IL-23, but not of IL-12,
in LCs, which in turn promotes Th17 in IMQ-treated skin
lesions.
IMQ induces IL-23 production from LCs after application of IMQ
Recently, it was postulated that IL-23, a cytokine driving
the development of IL-17- and IL-22-producing Th17 cells, is
functionally involved in the pathogenesis of psoriasis. Expres-
sion of IL-23 is increased in psoriasis lesional skin (Lee et al.,
2004), and increased numbers of Th17 cells are present
(Lowes et al., 2008). Application of IMQ leads to hyper-
plasia of the epidermis. In the same fashion, intradermal
injection of IL-23 in mouse skin results in erythema, a mixed
inflammatory infiltrate, and epidermal hyperplasia (Chan
et al., 2006). However, the source of IL-23 in psoriasis is
still unclear. To investigate the source of IL-23 in IMQ-treated
psoriasis-like skin, we first examined the expression of TLR7, a
receptor for IMQ, in the skin-composing cells. In the steady
state, LCs and Langerinþ and Langerin dDCs expressed
TLR7, whereas gd T cells, Gr1þ cells, and keratinocytes were
TLR7 negative irrespective of IMQ application (Figure 3a and
b). Recently, it has been reported that the IMQ-containing
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Figure 1. Langerhans cell–depleted mice show decreased IMQ-induced psoriasis-like skin inflammation. Langerinþ cells were depleted by DT in Langerin-DTR–
knocked-in mice. Langerinþ dDCs, but not Langerhans cells, repopulated in the skin 10 days later. C57BL/6J mice or Langerin-DTR–knocked-in mice were treated
daily with IMQ cream or control cream application on both ears for 5 consecutive days. (a) H&E-stained and immunohistochemical staining of Stat3, Ki-67
sections. (b) The ear swelling at day 6. (c) The numbers of Stat3- or Ki67-positive keratinocytes. Data are representative of four independent experiments and each
group consisted of more than four mice. *Po0.05 between indicated groups. Normal bar¼200mm, dotted bar¼100mm. dDCs, dermal dendritic cells; DT,
diphtheria toxin; DTR, DT receptor; H&E, hematoxylin and eosin; IMQ, imiquimod.
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cream ‘Aldara’ induces inflammation largely independently of
TLR7 and vehicle cream also promotes inflammasome activa-
tion in cultured keratinocytes (Walter et al., 2013). To examine
whether IMQ affects the expression of TLR7 to skin containing
cells, we measured the TLR7-mRNA expression by real-time
PCR. LCs, gd T cells, and KCs showed no remarkable change of
TLR7-mRNA; however, only Langerin dDCs showed high
expression of TLR7-mRNA (Figure 3c). As shown in
Supplementary Figure 1b online, Langerinþ dDCs disappeared
from IMQ-applied skin and expression of TLR7 from
Langerinþ dDCs could not be measured. We next examined
the IL-23-producing cells in the IMQ-applied skin by means of
flow cytometry. IMQ-applied skin contained more IL-23-produ-
cing cells than did control mice (Figure 3d and e). To identify
which cells produced IL-23, IMQ applied skins were analyzed
by flow cytometry stained by EpCAM, Langerin, gdTCR, and
Gr1. Only both EpCAM- and Langerin-positive cells or LCs
produced IL-23 after IMQ application to the skin (Figure 3f). In
control skin, B10% or less of LCs produce IL-23. However,
B80% of LCs produced IL-23 in IMQ-applied skin (Figure 3g).
These results suggest that IMQ administration induces IL-23
production in LCs.
Decreased infiltration of IL-17A-producing CCR6þ cd T cells in
LC–depleted skin after IMQ application
It has been reported that IL-23-responsive dermal gd T cells are
the major IL-17 producers in the skin (Cai et al., 2011), and
were revealed to express CCR6 in a murine model of psoriasis
(Mabuchi et al., 2011). We next investigated the production of
IL-17A and CCR6 expression from gd T cells in IMQ-treated
skin. IMQ cream was applied on both ears of LC/Langerinþ
dDC-depleted mice or on ears of only LC-depleted mice for 5
consecutive days. On day 6, epidermal-cell and dermal-cell
suspensions were prepared from IMQ-treated skin. When
IMQ was applied to non-DT-treated mice, increased
numbers of IL-17A-producing gdTCR midþ T cells were
detected in the epidermis, which were reduced in
LC-depleted mice (Figure 4a and b). On the other hand,
similar numbers of IL-17A-producing gdTCR midþ cells
were observed in the dermis of IMQ-treated skin regardless
of the presence of LCs (Figure 4c and d). These IL-17A-
producing gdTCR midþ cells were Vg4 and CCR6 positive
(Supplementary Figure 3 online). We also analyzed the IL-17A
positive cells in the CD4þ T-cell subset. The number of IL-
17A-producing CD4þ T cells increased in the IMQ-treated
epidermis and dermis. The number of IL-17A-producing
CD4þ cells was decreased in the dermis of LC- or Langerinþ
dDC-depleted skin (Figure 4e–h). These data indicate that LCs
induce infiltration of IL 17A-producing CCR6þ gd TCR midþ
Vg4þ cells into epidermis and psoriasis-like inflammation
after IMQ application.
LC-depleted and IMQ-treated mice show decreased numbers of
IL-12/23p40-positive cells and IL-17A-producing cd T cells at
regional lymph nodes
To analyze IL-23-producing cells and IL-17A-producing cells
in the draining lymph nodes, we next performed flow cyto-
metric analysis of regional lymph node cells at the end of a
5-day course of IMQ treatment. Compared with control mice,
mice that had just received 5 days of IMQ treatment exhibited
increased numbers of IL-23-producing major histocompatibil-
ity complex (MHC) class IIþ cells in the draining lymph
nodes. On the other hand, Langerinþ cell–depleted or
LC-depleted mice did not show any significant change in
the number of IL-23-producing cells (Figure 5a and c). These
IL-23-producing MHC class IIþ cells were positive for EpCAM
and Langerin, whereas IL-23-non-producing MHC class IIþ
cells were negative for EpCAM and Langerin (Figure 5b).
Surprisingly, almost all LCs in draining lymph nodes produce
IL-23. These results indicate that IL-23-producing MHC class
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Figure 2. IMQ application induces cytokine mRNA production in skin. IMQ cream was applied on both ears of LC/Langerinþ d DC–depleted mice or
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IIþ cells are LCs. Similarly, we found that the number of
IL-17A-producing gd T cells was significantly increased in the
IMQ-treated mice, and decreased in the Langerinþ cell–
depleted or LC-depleted mice (Figure 5d and e). We also
studied IL-17A-producing CD4þ T cells. The number of IL-
17A-producing CD4þ T cells was increased by treatment with
IMQ, which was decreased by depletion of Langerinþ cells or
only LCs (Figure 5f and g). Of note, the total number of IL-
17A-producing CD4þ T cells was less than a tenth of IL-17A-
producing gd T cells. Thus, gd T cells were the main source of
IL-17A in the draining lymph nodes of IMQ-treated mice, and
LC abrasion led to reduced numbers of IL-17A-producing gd T
cells. These results suggest that LCs are required for the IL-23
pathways that lead to IL-17 production by gd T cells in the
draining lymph nodes following IMQ treatment.
IL-23 from skin-derived LCs induces psoriatic skin inflammation
On the basis of the indication that IL-23 from LCs may
increase IL-17 production by gd T cells in the draining lymph
nodes, we further explored a role of IL-23 from LCs by
transplanting bone marrow (BM) cells of IL-23-deficient
(IL23KO) mice into X-ray-irradiated wild-type (WT) mice or
vice versa. As LCs are resistant to X-ray irradiation (Merad
et al., 2004), IL-23-producing LCs existed in the skin of X-ray-
irradiated WT mice. Two months after transplanting BM cells
of WT or IL23KO mice into X-ray-irradiated WT or IL23KO
mice, mice received topical applications of commercially
available IMQ cream on both ears for 5 consecutive days.
Ear thickness was measured on day 6 after the start of IMQ
application. Compared with IMQ-treated WT mice in which
both donors and recipients were WT, IL23KO mice, in which
both donors and recipients were IL23 KO mice, showed a
decrease in ear thickness (Figure 6). When transplanting BM
cells of WT mice into X-ray-irradiated IL23KO mice ear
thickness significantly decreased, whereas ear thickness did
not show any change compared with WT mice when
transplanting IL23KO BM cells into irradiated WT mice
(Figure 6). In Figure 6, WT control showed less swelling than
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mice shown in Figure 1b. This difference was possibly due to
the procedures of X-ray irradiation and BM transplantation.
WT mice in Figure 6 were X-ray irradiated once and then
transplanted with WT BM cells. Hence, total numbers and
distribution of lymphocytes in BM-transplanted WT mice in
Figure 6 are supposed to be different from those in normal WT
mice shown in Figure 1. Taken together, these data indicated
that IL-23 from LCs has a critical role in the IMQ-induced skin
inflammation, possibly that of modulating IL-17-producing gd
T cells in the draining lymph nodes.
DISCUSSION
In this report, we analyzed the pathomechanisms of psoriasi-
form dermatitis caused by IMQ in Langerin-DTR–knocked-in
mice. The IMQ-treated mouse skin resembles human plaque-
type psoriasis with respect to erythema, skin thickening,
scaling, and epidermal alterations (acanthosis, parakeratosis),
but these findings were not observed in a LC-depleted state. In
addition, LC-depleted mice showed decreased levels of Th17-
related cytokines in IMQ-treated skin lesions. Moreover, the
IMQ-treated skin of LC-depleted mice showed a decreased
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number of IL-17A-producing CCR6þ Vg4þ gdTCRþ mid
cells. These results suggest that LCs are required for the
development of murine psoriasis-like lesions induced by IMQ.
The importance of T cells in the pathogenesis of psoriasis is
supported by the response of patients to treatment with agents
that affect T-cell functions, such as cyclosporine. Several
cytokines have been implicated in the pathogenesis of psoriasis,
including TNF-a, IFN-g, IL-12, IL-17, IL-22, and IL-23 (van der
Fits et al., 2009). It has recently been reported that IL-23
expression is elevated in psoriatic skin lesions (Lee et al., 2004),
IL-23 induces psoriasis-like dermatitis (Chan et al., 2006),
polymorphisms in IL-23p19, IL-12/23p40, and IL-23R are
associated with the development of psoriasis (Capon et al.,
2007), and antibody against IL-12/23p40 can ameliorate
psoriasis in human skin (Krueger et al., 2007). IL-23 is
essential for the differentiation and survival of IL-17-producing
cells (Diveu et al., 2008), and IL-17 expression is augmented in
psoriatic skin. In addition, anti-IL-17 antibody administration
ameliorates psoriasis, indicating that IL-17 has an important role
in the pathogenesis of psoriasis (Di Cesare et al., 2009).
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IMQ application has been shown to induce IL-17A-produ-
cing gd T cells in the regional lymph nodes (Roller et al., 2012)
and IL-23p19 mRNA in mice (van der Fits et al., 2009).
However, the source of IL-23 in IMQ-treated areas remained
unclear. Here, we clearly demonstrated that LCs were the
major DC subset to produce IL-23 in the IMQ-treated skin,
and that IL-23 induced the infiltration of IL-17-producing
Vg4þ gdTCR midþ cells to the epidermis. These findings
are consistent with the recent studies, which demonstrated
that LCs are required for induction of IL-17-producing cells in
Candida albicans-infected skin lesions (Igyarto et al., 2011).
Recently, Wohn et al. (2013) reported that Langerin-negative
dDCs, rather than LCs, are responsible for IMQ-induced
psoriatic plaque formation Their conclusion was seemingly
contrary to ours in which LCs are indispensable for IMQ-
induced psoriatic plaque formation. These two apparently
contradictory experimental results using Langerin-DTR mice
may be caused by the different IMQ-induction methods used
by the two laboratories. Wohn et al. (2013) applied IMQ on
the back of mice, whereas we painted IMQ on the ears of
mice. In human beings, psoriasis is predisposed to take place
on knees and elbows. This predisposition may reflect the
difference in nature and the number of LCs and Langerin-
negative dDCs depending on the body sites. Moreover, time
course of DT application is different between the two
laboratories. Wohn et al. applied DT on day  3 and
painted IMQ, whereas we applied DT on day 1 and
applied IMQ. The time course of the DT application affects
the number of LCs as shown in Supplementary Figure 1 online.
These differences in the IMQ-applied areas and the timing of
DT application possibly gave rise to the different results. It
remains unclear whether IMQ directly acts on LCs in vivo.
Recently, it has been reported that Aldara cream, which
contains IMQ, induces inflammation largely independently of
TLR7, and keratinocyte death and IL-1 release also occur in
response to the vehicle cream in the absence of IMQ (Walter
et al., 2013). However, the role of IMQ for psoriatic skin
inflammation is still unclear. Intriguingly, the expression level
of TLR7 is rather high in dermal DCs compared with LCs. We
examined the production of IL-23 from LCs or dermal DCs by
stimulating them with IMQ in vitro. However, we could detect
no increase in IL-23 production from LCs or dermal DCs (data
not shown). Therefore, there may be other pathways besides
TLR7 that are involved in upregulating IL-23 production from
LCs. Therefore, it should be clarified whether IMQ directly acts
on LCs to produce IL-23 through TLR7 or indirectly induces LC
activation possibly through other immune cells, such as
plasmacytoid DCs or keratinocytes in the future.
Recently, CCR6 was shown to be a marker of peripheral IL-
17A-expressing gd T cells (Cua and Tato, 2010). These gd T
cells are observed following IL-23 intracutaneous injections
(Mabuchi et al., 2011). We now demonstrate that the accumu-
lation of IL-17A-producing CCR6þ gd T cells in the epidermis
and the draining lymph nodes is decreased in the LC-depleted
mice. This finding supports the hypothesis that LCs are the main
source of IL-23 for the induction of IL-17A-producing CCR6þ
gd T cells in the IMQ-induced dermatitis model. It was reported
that topical application of IMQ induces migration of LCs from
treated skin into the draining lymph nodes (Suzuki et al., 2000).
In line with this, we demonstrated the accumulation of IL-23-
producing LCs in the draining lymph nodes after IMQ
application and the induction of IL-17A-producing CCR6þ gd
T cells in the lymph node cell suspensions by IL-23. Therefore,
LCs may function in two ways. First, IMQ treatment induces the
accumulation of IL-23-producing LCs in the draining lymph
nodes for the induction of IL-17A-producing gd T cells. These
gd T cells migrate to the epidermal area of the IMQ-treated
skin, possibly via CCR6, where LCs may enhance the functions
or survival of IL-17A-producing gd T cells for the development
of psoriatic skin lesions.
Although IMQ-induced psoriasis-like skin lesions in mice
share some clinical and histological characteristics with
human psoriasis (Chan et al., 2006), there are several
differences between them. Most notably, the human
psoriatic skin lesion contains predominantly aT cells and not
many gd T cells. However, it has recently been reported that
dermal IL-17A-producing gd T cells were significantly
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Figure 6. Skin-derived IL-23-producing LCs have a critical role in IMQ-
induced skin inflammation. (a) Recipient WT C57BL/6J mice or IL-23 KO mice
(C57BL/6J background) underwent 9 Gy total body irradiation on day  1, and
received bone marrow single-cell suspensions from WT C57BL/6J mice or
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independent experiments and each group consisted of more than five mice.
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not significant; WT, wild type. *Po0.05.
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increased in human psoriatic skin (Cai et al., 2011), and that
production of the local chemokine CCL20, a ligand for CCR6,
is also increased in human psoriatic skin (Kryczek et al.,
2008). The increased frequency of gd T cells in psoriatic skin
suggests that gd T cells may be crucial in the development of
psoriasis not only in mice but also in humans.
In conclusion, here we demonstrate that IMQ treatment
induces IL-23 production by LCs in mice, and that LC
depletion resulted in attenuated IMQ-induced psoriasis-like
dermatitis with decreased numbers of infiltrating IL-17A-
producing gd T cells. In addition, these IL-17A-producing gd
T cells were induced by IL-23 in the draining lymph nodes.
These findings suggest that LCs seem to be the main cutaneous
DC subset in the development of IMQ-induced psoriasis.
MATERIALS AND METHODS
Mice and treatments
Seven 10-week-old C57BL/6J mice were obtained from SLC
(Shizuoka, Japan). Mice were maintained on a 12-hour light/dark
cycle under specific pathogen-free conditions. Langerin DTR–
knocked-in mice were generated (Kissenpfennig et al., 2005). To
deplete Langerinþ cells, mice were injected intraperitoneally with
DT (200 ng each; Sigma-Aldrich, St Louis, MO). IL23KO mice were
obtained from Keio University (Hasegawa et al., 2013). Protocols
were approved by the Institutional Animal Care and Use Committee
of the University of Occupational and Environmental Health. Mice at
8–11 weeks of age received a daily topical dose of 62.5 mg of
commercially available IMQ cream (5%) (Mochida Pharmaceutical,
Tokyo, Japan) on both ears for 5 consecutive days.
Generation of bone marrow chimera mice
To generate bone marrow chimera mice, recipient WT C57BL/6J
mice or IL-23 KO mice (C57BL/6J background) underwent 9 Gy total
body irradiation on day  1, and received bone marrow single-cell
suspensions from WT C57BL/6J mice or IL-23 KO mice on day 0
intravenously through the tail vein. Recipient mice were treated with
oral antibiotics for 2 months after transplantation.
Culture medium
RPMI-1640 (Gibco BRL Life Technology, Grand Island, NY) was
supplemented with 10% heat-inactivated fetal calf serum, 2 mM
L-glutamine, 5 10 5 M 2-mercaptoethanol, 10 5 M sodium pyr-
uvate, 25 mM HEPES, 1% nonessential amino acids, 100 units per ml
penicillin, and 100mg per ml streptomycin (all from Gibco).
Preparation of skin suspensions
Skin sheets from mouse ears were floated in 0.2% of trypsin in PBS
(pH 7.4; Sigma-Aldrich) for 30 min at 37 1C as described previously
(Tokura et al., 1994). The epidermis was separated from the dermis
with forceps in PBS supplemented with 10% fetal calf serum. Both
epidermis and dermis were minced and incubated for 1 h at 37 1C in
PBS with collagenase II (Sigma-Aldrich). The obtained cells were
filtered through a 40-mm filter.
Flow cytometry
Cells were immunostained with various combinations of fluores-
cence-conjugated mAbs and analyzed with a FACSCanto flow
cytometer (BD Biosciences, San Diego, CA) and FlowJo software
(Tree star, Ashland, OR). The expression levels of cell surface or
intracellular molecules and intracytoplasmic cytokines were analyzed
using the following antibodies: Alexa Fluor 488-conjugated
anti-gdTCR (clone; eBioGL3), PE-conjugated anti-IL-12/23p40
(clone; C17.8), IL-17A (clone; eBio17B7), IL-22 (clone; 1H8PWSR),
TNF-a (clone; MP6-XT22); PerCP-conjugated CD45 antibody (clone;
30-F11); biotin-conjugated anti-mouse CD207 (Langerin) (clone;
eBioL31); and PE-Cy7-conjugated anti-Ly-6G (clone; RB6-8C5)
(eBioscience, San Diego, CA) and anti-epithelial cell adhesion
molecule (EpCAM, clone; G8.8), Vg4 (clone; UC3-10A6), Vg5 (clone;
536) (Biolegend, San Diego, CA), and anti-TLR7 antibody (clone;
IMG4G6) (IMGENEX, San Diego, CA); APC-conjugated CCR6 anti-
body (clone; 140706) (BD Biosciences). All mAbs were used at a
concentration of 1–5mg per 106 cells, and each incubation was
performed for 30 min at 4 1C, followed by two washes in PBS
supplemented with 5% fetal calf serum and 0.02% sodium azide.
Viable cells were identified by 7-AAD uptake. For intracellular
cytokine staining, cells were incubated in the presence of Goldi Stop
(BD Biosciences) for 2 hours. Intracytoplasmic cytokines were
detected in permeabilized cell suspensions using a BD cytofix/
cytoperm Plus Kit (BD Biosciences).
Histology and immunohistochemistry
Paraffin-embedded skin specimens were prepared using routine
methods. The sections were stained with H&E. For immunohisto-
chemistry, sections were deparaffinized and hydrated by washing
sections in xylene followed by graded alcohol series. To unmask
antigens, sections were incubated in 10 mM citric acid (pH 6) at 95 1C
for 30 min. Sections were blocked with normal serum for 60 min at
room temperature followed by incubation with primary antibodies
(Stat3, Ki67; DAKO, Glostrup, Denmark) overnight at 4 1C. Samples
were washed and incubated for 60 min with secondary antibodies.
Real-time PCR
Total RNA was extracted from skin with the SVTotal RNA isolation
system (Promega, Madison, WI) according to the manufacturer’s
protocol. Murine IL-23p19, IL-12/23p40, IL-17A, IL-22, and TNF-a gene
expression levels were quantified in a two-step RT-PCR. cDNA was
reverse transcribed from total RNA samples using the TaqMan RT
reagents (Applied Biosystems, Foster City, CA). Target gene expression
was quantified using TaqMan Gene Expression Assay (Applied Bio-
systems) in the ABI PRISM 7000 sequence detection system (Applied
Biosystems). The probe was synthesized with VIC as a reporter dye
and Tamra as the quencher dye. The forward primer, reverse primer,
and Taqman probe were purchased from Applied Biosystems
(IL-23p19; Mm01160011_g1, IL-12/23p40; Mm00434174_m1,
IL-17A; Mm00439619_m1, IL-22; Mm00444241_m1, TNF-a;
Mm00443258_m1, TLR7; Mm00446590_m1). As an endogenous con-
trol for these PCR quantification studies, GAPDH gene expression was
measured using the TaqMan rodent GAPDH control reagents (Applied
Biosystems). Gene expression was calculated using the DDCt method.
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